1. Home
  2. MHO vs NRIX Comparison

MHO vs NRIX Comparison

Compare MHO & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MHO

M/I Homes Inc.

SELL

Current Price

$125.56

Market Cap

3.4B

ML Signal

SELL

Logo Nurix Therapeutics Inc.

NRIX

Nurix Therapeutics Inc.

HOLD

Current Price

$14.76

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MHO
NRIX
Founded
1976
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.4B
2.8B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
MHO
NRIX
Price
$125.56
$14.76
Analyst Decision
Buy
Buy
Analyst Count
4
14
Target Price
★ $156.67
$33.50
AVG Volume (30 Days)
311.7K
★ 3.4M
Earning Date
10-21-2026
10-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
★ 8.14
3.26
Revenue
★ $4,417,781,000.00
$76,987,000.00
Revenue This Year
N/A
$786.93
Revenue Next Year
$0.77
N/A
P/E Ratio
$15.50
★ $4.52
Revenue Growth
N/A
★ 99.31
52 Week Low
$113.40
$12.61
52 Week High
$163.66
$28.23

Technical Indicators

Market Signals
Indicator
MHO
NRIX
Relative Strength Index (RSI) 44.56 25.08
Support Level $124.70 $14.65
Resistance Level $127.01 $17.47
Average True Range (ATR) 4.52 1.22
MACD -0.02 -0.77
Stochastic Oscillator 19.91 0.23

Price Performance

Historical Comparison
MHO
NRIX

About MHO M/I Homes Inc.

M/I Homes Inc is an American construction company that focuses on residential construction. It consists of two distinct operations: homebuilding and financial services. The homebuilding operations are spread into the Midwest, Mid-Atlantic, and Southern regions, and the financial services operations support homebuilding operations by providing mortgage loans and title services to the customers of homebuilding operations. Homebuilding operations comprises a predominant portion of the revenue. The company builds homes and communities that target entry-level, move-up, and luxury homebuyers.

About NRIX Nurix Therapeutics Inc.

Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.

Share on Social Networks: